Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. CALSYN (calcitonine de saumon)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

CALSYN (calcitonine de saumon)

Medicine - Posted on Dec 24 2019
Active substance (DCI)
  • calcitonine de saumon
history (7)
  • 6/5/19

    CALSYN (calcitonine de saumon)

    Intérêt clinique insuffisant pour justifier son remboursement dans la maladie de Paget et l’hypercalcémie maligne en raison ...
    icône flèche
  • 3/4/15

    CALSYN (calcitonine de saumon)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 12/19/12

    CALSYN (calcitonine de saumon)

    CALSYN (calcitonine de saumon)
    icône flèche
  • 1/13/10

    CALSYN (calcitonine de saumon)

    CALSYN (calcitonine de saumon)
    icône flèche
  • 6/10/09

    CALSYN (calcitonine de saumon)

    Pas d’intérêt clinique démontré dans la prévention de la perte osseuse Médicaments de seconde intention dans le traitement d...
    icône flèche
  • 7/6/05

    CALSYN (calcitonine de saumon)

    CALSYN (calcitonine de saumon)
    icône flèche
  • 9/15/04

    CALSYN (calcitonine de saumon)

    CALSYN (calcitonine de saumon)
    icône flèche
Technical information
ATC code
  • H05BA01
Manufacturer
SANOFI-AVENTIS FRANCE
Presentation

CALSYN 50 UI/0,5 ml, solution injectable (code CIS : 60982072)
B/1 ampoule de 0,5 ml - Code CIP : 34009 340 657 6 7

CALSYN 100 UI/1 ml, solution injectable (code CIS : 60782552)
B/1 ampoule de 1 ml - Code CIP : 34009 340 658 2 8

All our publications
    Bone and cartilage diseases Congenital, genetic and rare diseases Drug therapy Metabolic diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq9mFFv2jAQx9/5FFHekwAtK50C1cbaDalVGQVt2ktlkqOYBTs92xT26ecQqqWTo7am7hMiTv6+3J1/91fis80q89aAgnLW81th0/eAJTyl7K7nTycXQdc/6zfiJVmTym0nYTNstX0vyYgQPb9YDWdAmAh/Xl1+Af08oN9veDGfLSGRT+5TkmbhNyIWVyQv7vHiNaeptwK54GnPz5XcXfViIVFH0X/g+FvkJIE42l+pri5vj6vX46gQe4GqEoCXhN0ZRYFZaSYKEZgcEAl3HLc18R5ZaVMxBsEVJjAicjFCvqYppMYt5iQTYLXJ/CG9AVxnIItNjOLRMlkJK3GyJJsx3A/NQX/SqwO5kUEzaJ102q2j427ntNm1SxZWUmWugn6JKM8xvW2fdo873dMIWJTovG1ZoH8SKjmjDIIUAkHUijPLmo04SpI5qhYVg6cN52gfhPtnuyKlIs/INlyK3DZVBIleBtRYcPcixRtMUIMq0zn7T5+pLIteGfV0jxFHEReUGnDFZA1NLsa2iRhwJmFTX1E7AMrNvhcpiLeT/cOZGf4jNctoYos6DSMFQk7Hw3rSvQckPhMBU3RHiR+UpfxBvD19qtV2FH2+A6hRVBemVVTmQ6vTsT5cv3Rr1Uykc4U8h0hziYpDcDNkc34oaHS3mqUee9V5m+78Etd6UOOYAksW6f58NHjOToC701UuGEW/nk9s2+a7Atze7P4apWnaqxbcjtUuBoDu09rYX9/15eF3YqcVmqGykDIXH6NoQYQ+LTpD4RzfbRBUZrI7g+9k8JdGqISpo9Bn5ZR8edVsD99ztuBQq7t/fm+pjXtIVHBAHUpOO6Pp8PztAf3P5zoLe/SEJu622XlSIilnrjyRmpkN0aEjQZeWXaDmw/V8Tmu+t9S2ZhyV33r6jTgqvvP0G38Bj50KDw==
hn6Z17Mk0N9DGK8E